|
Synonyms: Cejemly® (China) | CS-1001 | CS1001 | WBP-3155 | WBP3155
sugemalimab is an approved drug (China (2021))
Compound class:
Antibody
Comment: Sugemalimab is a fully human, high-affinity anti-programmed death ligand 1 (PD-L1) IgG4 monoclonal antibody. It is a checkpoint inhibitor class immuno therapeutic. In vitro, it competitively blocks the binding of human PD-L1 to PD-1 and CD80, and it induces T lymphocyte proliferation and enhances antitumour immunity [2].
|
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
